Lynch syndrome diagnostics: Decision-making process for germ-line testing

Clinical and Translational Oncology

Volumn 14, Issue 4, 2012, Pages 254-262

  Lastra, Enrique ^a   García González, María ^a   Llorente, Beatriz ^a   Bernuy, Coralina ^a   Barrio, M Jesús ^a   Pérez Cabornero, Lucía ^b   Durán, Mercedes ^b   García Girón, Carlos ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Decision making process; Germ line testing; Lynch syndrome; Molecular diagnostics

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

BRAF GENE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PROTOCOL; FAMILIAL CANCER; GENE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; GERM LINE; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MLH1 GENE; MOLECULAR DIAGNOSIS; MSH2 GENE; MSH3 GENE; MSH6 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PMS2 GENE; PRACTICE GUIDELINE; PROTEIN METHYLATION; REVIEW; REVISED BETHESDA GUIDELINE;

ADULT; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DECISION MAKING; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENETIC COUNSELING; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK;

EID: 84860769281     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0793-3     Document Type: Review

References (64)

1. Vasen HFA, Möslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362 (Pubitemid 46953715)
2. Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834 (Pubitemid 30243745)
3. Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269 (Pubitemid 43113031)
4. Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979-1985 (Pubitemid 40570891)
5. Lynch HT, Boland CR, Rodriguez-Bigas MA et al (2007) Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25:3534-3542 (Pubitemid 47310892)
6. Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788
7. Piñol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986-1994 (Pubitemid 40570892)
8. Lu KH, Schorge JO, Rodabaugh KJ et al (2007) Prospective determination of prevalence of Lynch Syndrome in young women with endometrial cancer. J Clin Oncol 25:5158-5164 (Pubitemid 350232246)
9. Balaguer F, Balmaña J, Castellví-Bel S et al (2008) Validation and extension of the PREMM 1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 134:39-46
10. Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751-2763 (Pubitemid 43974193)
11. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268 (Pubitemid 38256271)
12. Balmaña J, Stockwell DH, Steyerberg EW et al (2006) Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296:1469-1478 (Pubitemid 44465511)
13. Chen S, Wang W, Lee S et al (2006) Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479-1487 (Pubitemid 44465512)
14. Balmaña J, Valenzuela I, Rué M et al (2009) Comparación de los modelos predictivos para identificación de portadores de mutación en MLH1/MSH2/ MSH6 (síndrome de Lynch) en una cohorte española. XII Congreso Sociedad Española de Oncología Médica (SEOM). DOI:10.3252/pso.es.12seom.2009
15. Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10:293-300 (Pubitemid 352019113)
16. de Jong AE, van Puijenbroek M, Hendriks Y et al (2004) Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:972-980 (Pubitemid 38198898)
17. Shia J, Vakiani E, Guillem J et al (2008) Immunohistochemistry (IHC) as first-line screening tool for detecting colorectal cancer (CRC) patients at risk for Lynch syndrome: a 2-antibody panel is as predictive as a 4-antibody panel (Abstr). Mod Pathol 21[Suppl 1]:138A
18. Hall G, Clarkson A, Shi A et al (2010) Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology 42:209-213
19. Ley 14/2007, 3 de Julio, de Investigación Biomédica
20. Roncari B, Pedroni M, Maffei S et al (2007) Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC. Clin Genet 72:230-237 (Pubitemid 47300026)
21. Salashor S, Koelble K, Rubio C et al (2001) Microsatellite instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 81:535-541 (Pubitemid 32298799)
22. Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition-update of ICGHNPCC/INSiGHT mutation database. Dis Markers 20:269-276 (Pubitemid 40164099)
23. Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germline MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62:3485-3492 (Pubitemid 34651396)
24. Mangold E, Pagenstecher C, Friedl W et al (2005) Tumors from MSH2 mutation carriers show loss of MSH2 expression but many tumors from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 207:385-395 (Pubitemid 43025686)
25. Chang CL, Marra G, Chauhan DP et al (2002) Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 283:C148-C154 (Pubitemid 34670558)
26. Bindra RS, Crosby ME, Glazer PM et al (2007) Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26:249-260 (Pubitemid 47101664)
27. Shia J, Ellis NA, Klimstra DS (2004) The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch 445:431-441 (Pubitemid 39592745)
28. Zhang L (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 10:301-307 (Pubitemid 352019114)
29. Berends MJ, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26-37 (Pubitemid 34031695)
30. Buttin BM, Powell MA, Mutch DG et al (2004) Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 74:1262-1269 (Pubitemid 38669325)
31. Hendriks YM, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127:17-25 (Pubitemid 38962270)
32. Acharya S, Wilson T, Gradia S et al (1996) hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 93:13629-13634 (Pubitemid 26424170)
33. Marsischky GT, Filosi N, Kane MF et al (1996) Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10:407-420 (Pubitemid 26085996)
34. Bacher JW, Flanagan LA, Smalley RL et al (2004) Development of a ? uorescent multiplex assay for detection of MSI-high tumors. Dis Markers 20:237-250 (Pubitemid 40164096)
35. Suraweera N, Duval A, Reperant M et al (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123:1804-1811 (Pubitemid 35408304)
36. Goel A, Boland CR (2010) Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 26:47-52
37. Davies H, Bignell CR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
38. Oliveira C, Pinto M, Duval A et al (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22:9192-9196 (Pubitemid 38067995)
39. Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934 (Pubitemid 34976022)
40. Deng G, Bell I, Crawley S et al (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191-195 (Pubitemid 38114179)
41. Kambara T, Simms LA, Whitehall VL et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53:1137-1144 (Pubitemid 38961968)
42. Domingo E, Niessen RC, Oliveira C et al (2005) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24:3995-3998 (Pubitemid 40896411)
43. Domingo E, Laiho P, Ollikainen M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41:664-668 (Pubitemid 39208606)
44. Veganzones S, Maestro ML, Vidaurreta M et al (2007) Relación de la alteración dl gen BRAF y la metilación del gen reparador HMLH1en tumores colorrectales. Química Clínica 26:207-212 (Pubitemid 350084010)
45. Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875 (Pubitemid 28278073)
46. Kondo Y, Issa JP (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23:29-39 (Pubitemid 38221595)
47. Young J, Simms LA, Biden KG et al (2001) Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 159:2107-2116 (Pubitemid 33104265)
48. Chong S, Youngson NA, Whitelaw E et al (2007) Heritable germline epimutation is not the same as transgenerational epigenetic inheritance. Nat Genet 39:574-575 (Pubitemid 46676092)
49. Cropley JE, Martin DI, Suter CM (2008) Germline epimutations in humans. Pharmacogenomics 9:1861-1868
50. Dobrovic A, Kristensen LS (2009) DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol 41:34-39
51. Niessen RC, Hofstra RM, Westers H et al (2009) Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 48:737-744
52. Hitchins MP, Wong JJ, Suthers G et al (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356:697-705
53. Hitchins MP, Ward RL (2007) Erasure of MLH1 methylation in spermatozoa-implications for epigenetic inheritance. Nat Genet 39:1289 (Pubitemid 350035008)
54. Hitchins MP, Ward RL (2009) Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 46:793-802
55. Morak M, Schackert HK, Rahner N et al (2008) Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. Eur J Hum Genet 16:804-811 (Pubitemid 351865678)
56. Kovacs ME, Papp J, Szentirmay Z et al (2009) Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 30:197-203
57. Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 41:112-117
58. Nagasaka T, Rhees J, Kloor M et al (2010) Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 70:3098-3108
59. Lynch HT, Thibodeau SN, Snyder C et al (2010) Lynch syndrome TACSTD1 family with predominant colorectal cancer. J Clin Oncol 28[15s]:abstr 1500
60. Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407-414
61. Kempers MJ, Kuiper RP, Ockeloen CW et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49-55
62. Kloor M, Voigt AY, Schackert HK et al (2010) Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 29:223-227
63. Boland CR, Koi M, Chang DK et al (2008) The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside. Fam Cancer 7:41-52
64. Chang DK, Metzgar D, Wills C et al (2001) Microsatellites in the eukaryotic DNA mismatch repair genes as modulators of evolutionary mutation rate. Genome Res 11:1145-1146 (Pubitemid 32677287)